Selected 2004 Public Offerings

Selected 2004 Public Offerings

Publications

In 2004, we handled more than 75 public offerings and Rule 144A placements raising more than $20 billion. In the past five years, we have served as counsel to the issuer, underwriters or agents in more than 250 public offerings and Rule 144A placements raising over $100 billion, including more IPOs in the eastern United States—as both issuer and underwriters' counsel—than any other law firm in the country. Selected 2004 transactions are listed below:

  • Alnylam Pharmaceuticals— Initial Public Offering of Common Stock — $32,085,000 — Counsel to Issuer
  • Amdocs— Rule 144A Placement of 0.50% Convertible Senior Notes due 2024 — $450,000,000 — Counsel to Issuer
  • Barrier Therapeutics— Initial Public Offering of Common Stock — $75,000,000 — Counsel to Underwriters
  • Blackboard— Initial Public Offering of Common Stock — $88,550,000 — Counsel to Issuer
  • CapitalSource— Rule 144A Placements of Senior Convertible Debentures due 2034 — $555,000,000 — Counsel to Initial Purchasers
  • Casella Waste Systems— Rule 144A Placement of 9.75% Senior Subordinated Notes due 2013 — $51,100,000 — Counsel to Issuer
  • CB Richard Ellis Group — Initial Public Offering and Secondary Public Offering of Common Stock — $943,356,700 — Counsel to Selling Stockholder
  • CIT Group — Public Offerings of Medium-Term Notes — $12,040,000,000 — Counsel to Underwriters and Agents
  • Civica — Initial Public Offering of Ordinary Shares — £45,000,000 — Counsel to Underwriters
  • Corporación Andina de Fomento — Public Offerings of Floating Rate Notes — $350,000,000 — Counsel to Underwriters
  • Critical Therapeutics — Initial Public Offering of Common Stock — $42,770,000 — Counsel to Issuer
  • Cubist Pharmaceuticals — Follow-On Public Offering of Common Stock — $119,999,040 — Counsel to Underwriters
  • EPIX Medical — Rule 144A Placement of 3.00% Convertible Senior Notes due 2024 — $100,000,000 — Counsel to Initial Purchasers
  • Essex — Follow-On Public Offering of Common Stock — $114,000,000 — Counsel to Underwriters
  • Eyetech Pharmaceuticals — Initial Public Offering of Common Stock — $156,975,000 — Counsel to Issuer
  • First Marblehead — Follow-On Public Offering of Common Stock — $270,330,388 — Counsel to Issuer
  • Gatekeeper Systems — Initial Public Offering of Common Stock — £8,112,000 — Counsel to Issuer
  • GTx — Initial Public Offering of Common Stock — $78,300,000 — Counsel to Underwriters
  • John Hancock — Initial Public Offerings of Common Stock and Preferred Stock of Closed-End Funds — $1,221,400,000 — Counsel to Issuer
  • Idenix Pharmaceuticals — Initial Public Offering of Common Stock — $81,200,000 — Counsel to Issuer
  • LTX — Follow-On Public Offering of Common Stock — $132,825,000 — Counsel to Issuer
  • MapInfo — Follow-On Public Offering of Common Stock — $47,437,500 — Counsel to Issuer
  • MKS Instruments — Follow-On Public Offering of Common Stock — $115,316,020 — Counsel to Issuer
  • Momenta Pharmaceuticals — Initial Public Offering of Common Stock — $39,991,250 — Counsel to Issuer
  • NitroMed — Follow-On Public Offering of Common Stock — $87,553,982 — Counsel to Issuer
  • Open Solutions — Follow-On Public Offering of Common Stock — $90,614,328 — Counsel to Issuer
  • Pioneer — Initial Public Offerings of Common Stock and Preferred Stock of Closed-End Funds — $1,036,553,000 — Counsel to Issuer
  • PS Business Parks — Follow-On Public Offerings of Preferred Stock — $395,000,000 — Counsel to Underwriters
  • Red Hat — Rule 144A Placement of 0.50% Convertible Senior Debentures due 2024 — $600,000,000 — Counsel to Issuer
  • Sepracor — Rule 144A Placement of 0% Convertible Senior Subordinated Notes due 2024 — $500,000,000 — Counsel to Issuer
  • SS&C Technologies — Follow-On Public Offering of Common Stock — $100,912,500 — Counsel to Issuer
  • Timberland — Secondary Public Offerings of Common Stock — $399,173,389 — Counsel to Underwriters
  • Transkaryotic Therapies — Follow-On Public Offering of Common Stock — $90,000,000 — Counsel to Issuer
  • Vicuron Pharmaceuticals — Follow-On Public Offering of Common Stock — $74,502,250 — Counsel to Underwriters